Seven INNs use this variant, including marstacimab, an antibody to tissue factor pathway inhibitor (TFPI) used for treatment of hemophilia and well tolerated,70 also two PD‐1 antibodies, cadonilimab and penpulimab, approved in China for cancer therapy with a third, tagitanlimab under regulatory review. The gene discussed is TFPI; the disease is cancer.